National Institutes of Health, a Component of the US Dept. of Health & Human Services

Novartis Ag

Genzyme Corporation

Glaxosmithkline Biologicals Sa

Janssen Vaccines & Prevention B.v.

Norvartis Ag

Sabin Vaccine Institute

Genvec, Inc.

Cheng Cheng

Gary J Nabel

Douglas E Brough

John R Mascola

Yongping Yang

Gwo-Yu Chuang

Peter D Kwong

Baoshan Zhang

Tongqing Zhou

Michael Gordon Joyce

Ivelin Georgiev

Jeffrey C Boyington

Aliaksandr Druz

Nancy J Sullivan

Clement Asiedu

Stefano Colloca

Alfredo Nicosia

Riccardo Cortese

Guillaume Stewart-Jones

John Mascola

Marie Pancera

Jason Gorman

Barney S Graham

Masaru Kanekiyo

Virginia Ammendola

Yaroslav Tsybovsky

Mallika Sastry

Maria Grazia Pau

C Richter King

Jason G D Gall

Wing-Pui Kong

Jaap Goudsmit

Thomas J Wickham

Ulrich Baxa

Jingping Yang

Carl Hay

Priyamvada Acharya

Rita Chen

Paul Hallenbeck

Laura M Hales

Shanthi Ganesh

Ling Xu

Li Ou

Kai Xu

Joseph Van Galen

Seshidhar Reddy Police

Syed M Moin

Christopher Hwang

Kevin Liu

Rui Kong

Seul-A Bae

Xuejun Chen

Hongying Duan Holdsworth

Timothy Allan Johnson

Jonathan Wang

Jason Walther

Rebecca M Lynch

Neha Shah

Wing-pui Kong

Mohammed Zuber

Hui Geng

Timothy Johnson

Seshidar Reddy Police

Yen-Ting Lai

Carl M Hay

Rebecca Lynch

Paul L Hallenbeck

William J Enright

Provided herein are methods of culturing a mammalian cell in a liquid medium including poloxamer-188 at a concentration of 1.8 g/L or at a greater concentration than 1.8 g/L more or a liquid medium that includes a poloxamer-188 concentration that is selected based on one or more factors selected from the group of: pore size, pore type, gas flow rate, viable cell density in the medium, and markers related to cell stress.

Methods of culturing a mammalian cell

Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

HIV-1 ENV fusion peptide immunogens and their use

HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

Recombinant HIV-1 envelope proteins and their use

Embodiments of immunogens based on the outer domain of HIV-1 gp120 and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to prime an immune response to gp120 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

Glycan-masked engineered outer domains of HIV-1 gp120 and their use

Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.

Self-assembling insect ferritin nanoparticles

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

Chimpanzee adenoviral vector-based filovirus vaccines

HIV-1 Env fusion peptide immunogens and their use

Immunogens comprising a recombinant HIV-1 Env ectodomain trimer stabilized in a prefusion closed conformation and methods of their use and production are disclosed. In several embodiments, the immunogen can be used to elicit an immune response to HIV-1 in a subject.

Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens

Provided are recombinant adenovirus vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenovirus vectors can be used to induce protective immune responses against filovirus infection.

Adenovirus serotype 26 and serotype 35 filovirus vaccines

Growing community of inventors

Rockville, MD, United States of America

Cheng Cheng